Scientists Pinpoint TRIP10 as a Molecular Driver of Fetal Growth Restriction

Fetal growth restriction, a condition in which a baby fails to reach its expected weight in the womb, remains one of the most stubborn problems in modern obstetrics. It is a leading cause of stillbirth, neonatal death, and lifelong health complications, yet clinicians still lack reliable molecular tools to predict it, and researchers have only a fragmentary understanding of what goes wrong inside the placenta when a fetus stops growing. Now, a team of researchers in China has combined large-scale gene screening with laboratory experiments to identify a single gene, TRIP10, whose abnormal activity appears to sit at the heart of the disorder. The study, published in Reproductive Sciences, suggests that this gene acts as a brake on the very cells that a developing placenta needs to invade and remodel maternal tissue, offering both a candidate biomarker and a possible therapeutic target for a condition that has long defied intervention.

The research, led by Xinjun Li and Shengpu Wang with colleagues at hospitals affiliated with Hebei Medical University, began not at the laboratory bench but in public data repositories. The team mined two transcriptome datasets, GSE114691 and GSE24129, from the Gene Expression Omnibus, comparing gene activity in placental samples from pregnancies affected by fetal growth restriction against normal controls. The comparison revealed a striking molecular signature: 5,788 genes were differentially expressed between the two groups, with 1,450 switched to higher activity and 4,338 dialed down. That scale of disruption, affecting thousands of genes at once, underscores how profoundly the placental environment is altered when fetal growth falters, and it also illustrates why single-gene studies have struggled to untangle the condition’s causes.

To make sense of this flood of data, the researchers turned to functional enrichment analysis, a computational method that groups genes by the biological processes they participate in. The picture that emerged was coherent and biologically telling. The genes that were downregulated in growth-restricted placentas clustered around mitochondrial function, aerobic respiration, and amino acid metabolism, pointing to an energy crisis within placental tissue. In other words, the cellular power plants of the placenta appear to be running at reduced capacity, and the metabolic machinery that processes amino acids, the raw material for building fetal tissue, is similarly blunted. Meanwhile, the upregulated genes were associated with cell adhesion and histone modification, hinting at altered cell-to-cell architecture and changes in how DNA is packaged and read inside placental cells.

Identifying thousands of dysregulated genes is one thing; finding the handful that truly matter is another. To narrow the field, the team applied weighted gene co-expression network analysis, or WGCNA, a technique that organizes genes into modules based on patterns of coordinated activity across samples. The analysis produced 19 such modules, and one of them, labeled the darkorange module, showed the strongest positive correlation with fetal growth restriction. Genes in this module rose and fell together in ways that tracked the disease state, marking it as the most promising region of the transcriptomic landscape for further interrogation.

From that module, the researchers deployed LASSO regression, a statistical method that penalizes complexity and is widely used to distill large panels of candidate predictors down to a compact, robust set. The procedure selected eight candidate genes. The team then tested each against an independent validation dataset, looking for a gene whose behavior held up outside the data in which it was originally found. Only one passed that test cleanly: TRIP10, which showed consistent and significant upregulation in the validation set. Just as importantly, TRIP10 demonstrated excellent diagnostic performance, achieving an area under the curve of 0.906, a value close to 1.0 that indicates the gene’s expression levels separate growth-restricted placentas from healthy ones with high accuracy.

Computational findings in genomics are notoriously fragile, so the team moved to confirm the result at the protein level. Using Western blot analysis, a laboratory technique that detects specific proteins in tissue samples, they found that TRIP10 protein was significantly elevated in placental tissues from fetal growth restriction cases, matching the RNA-level signal. This convergence of transcriptomic and proteomic evidence is critical, because genes that are transcribed more abundantly do not always yield more protein, and it is protein, ultimately, that does the work of the cell. With both lines of evidence aligned, TRIP10 moved from statistical curiosity to credible biological suspect.

The next question was what TRIP10 actually does, and here the researchers turned to JEG-3 cells, a widely used laboratory model of human trophoblasts, the specialized cells that form the placenta’s interface with the mother. In a healthy pregnancy, trophoblasts must migrate and invade into the uterine wall, remodeling maternal blood vessels to secure an adequate blood supply for the fetus. When that invasion is shallow or incomplete, the placenta cannot deliver sufficient oxygen and nutrients, and fetal growth suffers. The team manipulated TRIP10 expression in these cells in both directions and measured the consequences. When they knocked TRIP10 down, cell migration and invasion were significantly enhanced. When they overexpressed the gene, those processes were suppressed. The results establish TRIP10 as a negative regulator of trophoblast migration and invasion, precisely the functions that are impaired in fetal growth restriction.

The biology of TRIP10 makes this finding especially intriguing. The gene encodes a protein involved in regulating Cdc42, a master molecular switch that governs cell polarity, shape, and movement, and it has been implicated in the formation of cellular junctions and in signalosome complexes in other tissues. A gene that controls the cytoskeletal machinery of cell movement, when overactive in the placenta, would be expected to restrain exactly the invasive behavior that trophoblasts need to perform. The new data suggest that TRIP10 dysregulation may contribute to impaired placental development, providing a mechanistic link between a single gene and a whole-pregnancy disorder. The downregulated metabolic pathways seen in the enrichment analysis may represent downstream consequences of a placenta that never properly established itself in the first place.

The clinical implications are twofold. First, TRIP10’s strong diagnostic performance raises the possibility of a molecular test to complement the ultrasound-based biometric measurements that currently define the standard of care. Screening for fetal growth restriction remains imperfect, and the condition is frequently underdiagnosed, so biomarkers that flag at-risk pregnancies earlier could allow closer surveillance and better-timed delivery decisions. Second, if TRIP10’s suppression of trophoblast invasion is confirmed as a causal driver rather than a bystander effect, it opens a path toward therapies aimed at restoring normal trophoblast behavior. That prospect remains distant, as the current evidence comes from a cell line and placental tissue rather than animal models or clinical trials, but it gives researchers a concrete molecular handle on a process that has been almost entirely opaque.

The study, supported by the Medical Science Research Project of Hebei and approved by the ethics committee of the Fourth Hospital of Hebei Medical University, exemplifies a workflow that is becoming the gold standard in translational genomics: mine public datasets, use network analysis and machine learning to distill candidates, validate in independent cohorts, and then confirm function experimentally. By following that path, the team has taken TRIP10 from an anonymous entry in a gene expression matrix to a named suspect in one of obstetrics’ most consequential mysteries. Larger studies across diverse populations will be needed to confirm the gene’s diagnostic value and to clarify whether it drives fetal growth restriction or merely marks it, but the finding offers something the field has lacked: a specific, testable molecular target in the placenta, and a reason to believe that the roots of fetal growth restriction may be within reach of both earlier detection and, eventually, intervention.

Subject of Research: Identification of the gene TRIP10 as a dysregulated regulator of trophoblast function in fetal growth restriction

Article Title: TRIP10 as a Key Regulator in Fetal Growth Restriction: a Study Integrating Bioinformatics Screening with Experimental Validation

Article References: Li, X., Xu, S., Zhang, X., Lian, W., Liu, G., & Wang, S. (2026). TRIP10 as a Key Regulator in Fetal Growth Restriction: a Study Integrating Bioinformatics Screening with Experimental Validation. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02222-4

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02222-4

Keywords: fetal growth restriction, TRIP10, placenta, trophoblast, bioinformatics, WGCNA, LASSO regression, gene expression, biomarker, cell migration, Reproductive Sciences, placental development